study question: Is it feasible to screen women with idiopathic recurrent miscarriage (RM) for high uterine natural killer (uNK) cell density and then randomize them to prednisolone or placebo when pregnant? summary answer: It was feasible to recruit women with idiopathic RM into a 'screen and treat' trial despite their desire for active medication. what is known already: Clinical trials of immunotherapy in women with idiopathic RM have failed to substantiate efficacy in preventing miscarriage. Preimplantation uNK cell density is higher in women with RM and can be reduced with prednisolone. study design, size, duration: In a pilot RCT, 160 eligible women were screened with an endometrial biopsy and those with high uNK cell density were invited to return when pregnant for randomization to prednisolone (20 mg for 6 weeks, 10 mg for 1 week, 5 mg for 1 week) or identical placebo tablets. Randomization was by random number generation and patients, clinicians and outcome assessors were blinded to allocation. The study size and duration was determined by funding, which was for a feasibility trial, for 2 years, sufficient to screen 150 women and randomize 40 women. The outcome measures were recruitment rate, women's perspectives, compliance, live birth and miscarriage rates and pregnancy complications.
Introduction
Recurrent miscarriage (RM), defined as the loss of three or more consecutive pregnancies, is a distressing condition for patients and clinicians for which there are few treatments of proven efficacy. All Cochrane reviews of RM suggest that further trials are needed (Empson et al., 2005; Porter et al., 2006; Hass and Ramsey, 2008; Kaandorp et al., 2009; Kowalik et al., 2011 ). An endometrial contribution to RM has been frequently suggested, however, there are no treatments of proven efficacy based on endometrial pathology. The involvement of an immune mechanism in RM has also been proposed. However, trials of immunotherapy in women with idiopathic RM have not demonstrated benefit in improving subsequent live birth rates in these women (Porter et al., 2006; Stephenson et al., 2010) . One potential solution to this situation would be a test that identifies the subgroup of women with RM that could benefit from treatment (Porter et al., 2006) .
Uterine natural killer (uNK) cells have been postulated to play a role in reproductive failure, including RM, owing to the temporal and spatial distribution of these cells. They form the largest population of leucocytes in the endometrium, varying in density throughout the menstrual cycle (Bulmer et al., 1991) . UNK cells increase in density towards the mid-luteal phase and, if implantation occurs, they peak in density in the first trimester of pregnancy. UNK cells are detected near endometrial glands and blood vessels, and are adjacent to trophoblast cells in early pregnancy. Direct antigen-receptor interactions between uNK cells and extravillous trophoblast occur (Moffett-King, 2002 ) and polymorphisms in the uNK cell receptor and trophoblast antigen have been associated with RM (Hiby et al., 2008) . A function of uNK cells is to regulate endometrial angiogenesis, an important factor in implantation (Hanna et al., 2006; Quenby et al., 2009) .
Many studies have associated a high density of uNK cells with RM (Lachapelle et al., 1996; Clifford et al., 1999; Quenby et al., 1999; 2005 Tuckerman et al., 2007) . However, it remains debatable whether high uNK cell density is associated with subsequent adverse pregnancy outcomes. Our systematic review of this association found only two studies that reported pregnancy outcomes, with small numbers of women in each study . The evidence that high levels of uNK cells are predictive of subsequent miscarriage in idiopathic RM remains inconclusive.
UNK cells express glucocorticoid receptors (Henderson et al., 2003) . A prospective study carried out to investigate the effect of steroids on uNK cells showed a significant decrease in uNK cell density in women with RM after 3 weeks of prednisolone treatment (Quenby et al., 2005) . Prednisolone was chosen as the placenta metabolizes it via 11 beta-hydroxysteroid dehydrogenase 2. Thus, very little of the drug administered orally reaches the fetus (Addison et al., 1993) . Furthermore, prednisolone has been given in the first trimester of pregnancy to many women, with asthma (Nelson-Piercy, 2001), rheumatoid arthritis (Ostensen, 2001 ) and hyperemesis gravidarum (Yost et al., 2003) with no ill effects, even in recent trials with high-quality post-natal followup Miller et al., 2004) .
Given the limited evidence about the efficacy of prednisolone in RM further trials are needed. A large trial with adequate sample size is needed to test whether prednisolone, when given to women with a high density of uNK cells, has an impact on important clinical outcomes. Such a large study would face a range of obstacles and this feasibility study was designed to address some of these before designing a large definitive trial. Our aim was to assess whether women with RM would attend for a screening visit consisting of an endometrial biopsy to assess uNK cell density and, if screen positive, return when pregnant for randomization to placebo or prednisolone. We also aimed to assess women's perceptions of the trial and whether prednisolone, which is known to have side effects, would be tolerated in pregnant women with RM.
Methods

Study population
The trial was advertised nationally in the UK using conference lectures, newspaper, radio and television media, trial website and the Miscarriage Association website and locally. The women then discussed the trial with their local consultant or general practitioner who were persuaded by the women to refer them to one of two research clinics run by a single investigator (SQ). Recruitment into the study occurred between August 2008 and August 2010. Women who were ,40 years old and had three or more consecutive miscarriages were eligible for this study. The exclusion criteria for recruitment were pregnancy or a known factor that could be contributory to RM. These factors were antiphospholipid syndrome (two positive tests for immunoglobulin (Ig)G or IgM anticardiolipin antibodies or lupus anticoagulant), abnormal parental karyotype, known congenital uterine abnormality (septate or bicornuate uterus), abnormal thyroid function tests or a positive thrombophilia screen (factor V Leiden mutation, activated protein C resistance, prothrombin G20210A mutation, protein C or S deficiency or antithrombin deficiency) (RCOG, 2011) . Women were also not eligible if there was a contraindication to prednisolone treatment, such as hypertension, diabetes mellitus, obesity with a BMI . 35 kg/m 2 or severe mental health problems.
Women's perspective
The women's perspective was assessed with a simple questionnaire asking whether they thought they had an endometrial cause to the miscarriages and their preference of treatment allocation if they had an option to choose one rather than be randomized. This questionnaire was given to 78 consecutive women at the screening visit in the middle phase of the trial (January to December 2009).
Study design and treatment regimes
Women were advised to use barrier methods of contraception for one cycle. They then telephoned the clinic at the time of the urinary LH surge and were given an appointment at one of two research clinics both run by a single investigator, 6 -9 days later. At this appointment written informed consent was obtained for screening and women had a Figure 1 CONSORT statement flow diagram.
Recurrent miscarriage prednisolone trial transvaginal ultrasound scan of their pelvis and an endometrial biopsy (Wallach endocell sampler) was taken and put in formalin. The biopsy was embedded in paraffin, cut into sections and immunohistochemistry was used to identify uNK cells using an antibody to CD56 (Quenby et al., 1999 (Quenby et al., , 2005 ). CD56 was used as previous work had found that CD56+ cells discriminated between women with RM and those with normal obstetric histories better than other leucocyte markers, including CD16 (Quenby et al., 1999) . The uNK cell density was determined as the percentage of uNK cells relative to stromal cells. A cut-off of normality of 5% uNK cell density was used, as determined by previous studies of women with RM compared with those with normal obstetric histories where 5% represented the upper end of the interquartile range of control samples (Quenby et al., 1999 (Quenby et al., , 2005 ). However, a lower inter-and intra-observer variation is needed for clinical trial entry than for crosssectional comparative studies published in this area (Clifford et al., 1999; Quenby et al., 1999 Quenby et al., , 2005 Quenby et al., , 2009 Tuckerman et al., 2007; Mariee et al., 2012) . Hence, an improved methodology of uNK cell density assessment was developed specifically for this trial and a standard operating procedure was adhered to. This involved: (i) using the same control samples in each batch to ensure the staining was consistent; (ii) excluding glands and vessels from the count; (iii) only counting CD56+ cells near the epithelial edge as uNK cell density varies with endometrial depth; (iv) counting a minimum of eight randomly selected high powered fields and 5000 stromal cells per patient; (v) defining a CD56-positive cell as one that had a nucleus (CD56 stains the cell surface); (vi) using image analysis and (vii) external quality control advice from Dr Bulmer . Women were informed of their results by letter and had a further telephone consultation. Women with a normal uNK cell density of ,5% were discharged back to standard care, while those with a density of ≥5% uNK cells were advised to contact the clinic again as soon as they were pregnant (4-6 weeks after their last menstrual period) for randomization into the trial.
Pregnancy was confirmed by a urinary test for b-hCG and a transvaginal ultrasound scan was performed. If the pregnancy location was uncertain, women were still invited to be randomized and follow up ultrasound scans were arranged. Written informed consent was obtained for a second time prior to randomization, to either prednisolone or placebo. Randomization was performed using a computerized random number generator in blocks of 20. The allocation list was kept in pharmacy where a dedicated pharmacist dispensed the tablets. Both the trial investigators and women were blinded to the treatment allocation. Both prednisolone (manufactured by Wockhardt UK Ltd) and placebo (manufactured by Quay Pharmaceuticals) tablets were similar in size and colour and dispensed in identical packaging. Women took four tablets a day for 6 weeks, two tablets a day for 1 week and then one tablet a day for the final week. Women were advised to take the tablets early in the morning. The active tablets consisted of 5 mg of prednisolone. Once randomized, patients were reviewed fortnightly with ultrasound scans until 14 weeks gestation. Growth scans were carried out at 28 and 34 weeks gestation, in addition to routine antenatal care. All women were followed up 6 weeks after delivery, either in the clinic or through a telephone consultation. Women who miscarried while taking trial medication were advised to tail off medication slowly, two tablets a day for 3 days then one tablet a day for 3 days. Women were counselled on the options of conservative, medical or surgical management for the miscarriage.
Outcome measures
The main outcomes measures of interest were: recruitment rate for screening and randomization, women's perspective about the trial procedures, intervention and willingness for and compliance with randomization.
All randomized women had compliance to medication assessed through a daily medication log and side effects were assessed using a proforma completed at the end of first trimester during a clinic review. A diary was also completed by the woman whilst taking the trial medication. The women were asked to record any unusual symptoms, hospital admissions or side effects. Fetal heartbeat present at randomization 3 1
Data are mean (range) or n (%). All comparisons between groups NS.
Clinical outcomes were live birth, mode of delivery, gestational age at delivery, congenital or neonatal abnormality, and pregnancy complications including intrauterine growth restriction (IUGR) (,5th centile of customized birthweight chart), macrosomia (.90th centile of customized birthweight chart), gestational hypertension, pre-eclampsia and gestational diabetes mellitus. The outcomes for miscarriages included: gestation week at which miscarriage occurred; type of miscarriage (biochemical loss; sac loss or fetal loss as defined by the European Society of Human Reproduction and Embryology ); karyotype of miscarried pregnancies and intrauterine fetal death (fetal death after 24 weeks gestation).
Case report forms (CRF) were completed at 14 weeks' gestation, after delivery and 6 weeks after delivery. Completed CRFs were given to an independent research administrator who entered the information on a database and kept them as confidential trial documentation. Reports were generated to the data monitoring committee (DMC) as necessary.
Study oversight
The approval to conduct the trial was granted by the Liverpool Local Research Committee, and Medicines and Healthcare products Regulatory Agency. The trial was included on the National Institute for Health Research (NIHR) Clinical Research Portfolio (NIHR CRN ID: 6567) and was registered with the European and international clinical trials database (EUDRACT No: 2005-003307-36, ISRCTN28090716) . The trial was co-sponsored by Liverpool Women's NHS Foundation Trust and the University of Liverpool. The trial protocol was published (Tang et al., 2009) . A trial steering committee and trial management group supervised and managed the trial and was responsible for approving the core protocol and any subsequent amendments. They met every 6 months. A DMC which was independent of the trial investigators provided independent review of unblinded data after 1 year of recruitment to ensure that no harm was caused by the treatment. The accuracy of CRFs to the case notes was intermittently checked by the sponsors of the trial at random. There was also double entry data management to minimize human error.
Sample size
As this study involved a controversial area with novel methodology, the feasibility of this trial RCT was uncertain. Hence a significant number of women needed to be recruited to prove feasibility. We obtained funding for 2 years that was sufficient to screen 150 women, and randomize 40 women. The trial was not designed to test efficacy or safety of the intervention but was designed to demonstrate feasibility.
Statistical analysis
Data were cleaned prior to any analysis. The proportion of women who screened positive for a high uNK cell density and returned for randomization into the trial was recorded. Their willingness for randomization was also assessed using the screening visit questionnaire. Demographic information for all women screened was tabulated. Similarly, summary statistics of demographic information relating to the allocation groups of women who were randomized were tabulated and examined to ensure the treatment and placebo groups were similar. Compliance with medication and side effects of steroids were evaluated. All adverse events were also noted according to allocation group. Clinical outcomes of live birth rate in each group were expressed as a risk ratio (RR) with 95% confidence intervals (CIs). Other outcomes, such as the rates of miscarriage, type of miscarriage (biochemical, sac or fetal loss), karyotype of miscarried pregnancies, gestational age at delivery, mode of delivery and pregnancy complications, were tabulated.
Results
Feasibility of recruitment
In the 2-year period 160 eligible women consented to be screened for uNK cell density (Fig. 1) and 40 women were randomized. Hence the recruitment rate met the planned targets. Of these 160 women, 72 (45%) were found to have ≥5% uNK cells, and were suitable to be randomized to either prednisolone or placebo when pregnant. Eighty-eight women were informed of the normal results and discharged back for standard care. Of the 32 women with ≥5% uNK cells and not randomized, 14 conceived but declined randomization, 3 decided to seek assisted reproduction and 15 women did not contact the clinic again because they did not conceive before the trial ended.
The demographic characteristics of women in both screen positive (≥5% uNK) and screen negative groups were similar (Table I ). The Recurrent miscarriage prednisolone trial demographic characteristics of those who agreed to be randomized were similar to those who were not, as seen by comparing Tables I  and II . The demographic characteristics of the patients randomized to placebo were similar to those randomized to prednisolone (Table II) .
Patient perspective
Almost half the women who attended for screening (78/160, 49%) were given and completed a questionnaire. Fifty-three (68%) women thought they had abnormal uNK cells, and thus attended screening. There was little relationship between the patient's perception of their result and their actual result: 23 of 53 (43%) who thought they had high uNK cell density did so and 7 of 17 (41%) who thought they had normal uNK cell density did so. Sixty-six (85%) women wanted prednisolone treatment if they were given an option (Fig. 2) . Many commented that the desire for a child far outweighed the experience of side effects and potential risk of any empirical treatment. Of those wanting active medication, 27 (41%) were found to have high uNK cells and 18 of the 27 (67%) were randomized. Eleven (14%) women had no preference for either group and four (36%) were found to have high uNK cells. Of these four women, two (50%) were randomized. Only one woman preferred to have placebo because of a fear of side effects from prednisolone. She was found to have a high uNK cell density, and returned for randomization when pregnant.
Acceptability of trial medication
Side effects were more commonly reported in the 20 women in the prednisolone group compared with the placebo group (Table III) . However, none were severe enough for women to stop taking medication and compliance with treatment was reported to be 100%. Women were advised to discontinue treatment when a miscarriage was confirmed. Despite the fact that women were advised to take the tablets early in the morning, the most common side effect was insomnia (Table III) . There were no reports of bruising or infection. In the patient diaries, eight women in the prednisolone group reported additional side effects. Two women reported increased appetite, one headache and hallucinations, one reported palpitations, one reported hirsutism, one worsening of her irritable bowel syndrome and two complained of nausea. In the placebo group, two complained of side effects (one headache and one bloating). There were no suspected unexpected serious adverse reactions (SUSAR).
Clinical outcomes
The live birth rate was 12/20 (60%) in the prednisolone group and 8/20 (40%) in the placebo group, and this was not significant (RR 1.5, 95% CI 0.8 -2.9) (Table IV) . There was only one pre-term delivery of ,37 weeks in the prednisolone group, and all others delivered at term. The Caesarean section rate was high in both groups but the reason for this was not clear. two groups, with no pregnancy complications of IUGR or macrosomia. There were also no reports of gestational hypertension, pre-eclampsia or gestational diabetes in either group. There were no adverse fetal outcomes. In one baby in the prednisolone group mild hearing problems were detected post-natally and in one baby in the placebo group renal tract abnormalities were detected at an antenatal check. Both the admissions to neonatal unit were for observation only and both babies were discharged home with the mother. The baby from the prednisolone group had mild jaundice and hypoglycaemia and the baby in the placebo group was treated with antibiotics for the renal tract abnormality.
There were 8/20 (40%) miscarriages in the prednisolone group and 12/20 (60%) miscarriages in the placebo group (Table IV) . There were similar numbers of biochemical, sac and fetal losses in both groups. Karyotypes of six miscarriages were obtained, three in each group, and 67% were normal in each group. Products of conception were not readily available for the other miscarriages as most women chose to have conservative or medical management of the miscarriage. Women with a very high uNK density (.10%) had poor outcomes, with 3/3 on placebo miscarrying and 2/4 on prednisolone miscarrying (Fig. 3) . In this feasibility trial, the live birth rate in the placebo group was low compared with that in the control group of other RCTs in similar populations of women but this finding did not reach statistical significance (Table V) .
Discussion
The lack of proven efficacy in current RCTs of miscarriage prevention suggests that a new approach to RM is needed. This trial has found that a stratification and treatment trial based upon endometrial uNK cell density is feasible and acceptable to the patients thus allowing new approaches to the management of RM to be developed. Enthusiasm of women for the trial was demonstrated by the fact that some women travelled from all over the UK to participate in this study, funding their own transport both for screening and randomization visits. Despite the fact that the majority of screen positive women had a preference for the treatment arm, over half returned to be randomized to that or placebo. It was the women's commitment to this trial that enabled us to complete the planned recruitment with the limited budget provided in the pre-agreed time frame. Although side effects were reported by the women, compliance with treatment was reported to be 100% with no discontinuation because of these side effects. Reassuringly, there were also no SUSARs reported from treatment with prednisolone.
There has been a series of publications providing convincing evidence for a defect in endometrial stromal cell differentiation in RM (Salker et al., 2010 (Salker et al., , 2011 . This defective decidualization correlates with a uNK cell density .5% and a lack of 11-b hydroxyl steroid dehydrogenase type 1 in stromal cells (Kuroda et al., 2012) . 11-b hydroxyl steroid dehydrogenase type 1 actives cortisol, hence administration of the glucocorticoid prednisolone may overcome this deficit. Furthermore, prednisolone reduced endometrial uNK cell density, the production of angiogenic cytokines known to be secreted by uNK cells and endometrial angiogenesis Lash et al., 2011) . Hence we argue that a new approach is needed for effective treatment for RM, one based on stratification of risk using an endometrial test and then treatment. Furthermore, we have demonstrated that it is feasible to fully test this new approach with high-quality RCTs.
In contrast, recently published high-quality RCTs have been pragmatic and have failed to demonstrate effective prevention of subsequent miscarriage using heparin and/or aspirin (Laskin et al., 2009; Clark et al., 2010; Kaandorp et al., 2010; Visser et al, 2011) and intravenous immunoglobulin G (Stephenson et al., 2010; Ata et al., 2011) . This lack of proven efficacy may be related to the tradition of stratifying women according to the clinical history. This means that the participants can be at high or low risk of subsequent miscarriage when randomized in This trial has a number of limitations. Importantly, as a feasibility study the trial was not powered to test the efficacy or safety of prednisolone. There were some problems with the trial design that should be addressed in future trials of this nature. The aim of the trial was to treat women who had an endometrial component associated with their pregnancy losses. Hence it was logical to include women with a history of very early or biochemical losses. However, the location of the pregnancy is uncertain in biochemical losses, as they could have been tubal pregnancies. Thus, including women with biochemical losses and those with previous ectopic pregnancies may explain the ectopic pregnancies in women in this trial (3/40). The trial protocol stated that we would initiate the medication at '4-6 weeks gestation'. This led to inconsistency in start date of the trial medication, four women (two in each group) started immediately after a positive pregnancy test at 4 weeks gestation, others started after an ultrasound scan revealed an intrauterine sac at 4-5 weeks' gestation (18 in each group). This meant that some women were included (ectopic pregnancy, biochemical pregnancy) in whom the active treatment could not have prevented their loss. Furthermore some women were randomized before (15 prednisolone, 17 placebo) and others after (3 prednisolone, 1 placebo) a fetal heart was visualized. In all cases who were randomized before the fetal heart was visualized, the gestation sac size was consistent with the last menstrual period date. In future trials we recommend that the time of entry to the trial is more consistent. There was a low rate of karyotype results from the miscarriages (30%) for the following reasons: some women had biochemical miscarriages, with no tissue for karyotyping, some had medical and conservative management for their miscarriage. We could not determine what type of pregnancy loss prednisolone could potentially prevent, as the number of losses in each category was too small. The multiplicity of outcomes meant that none would reach a significance threshold of 0.01 needed for all outcomes even in a larger trial. Hence in future trials we recommend that the primary outcome measure is live birth rate after 24 weeks' gestation. The limited financial resources meant that it was not possible to follow up obstetric outcomes in all the women screened and this meant that important information was lost.
Currently, uNK cell density assessment varies greatly from laboratory to laboratory and there is also some variation between menstrual cycles (Mariee et al., 2012) . It is important to realize that many laboratories undertaking uNK cell density assessment use different methodologies, so the cut-off of normality cannot be compared between publications. Indeed there are insufficient prospective data published to validate uNK cell density as a clinical test . Mariee et al. (2012) , Tuckerman et al. (2007) and Clifford et al. (1999) counted CD56+ cells in the deeper layers of the endometrium where CD56+ cell density is considerably higher and the variation greater than in the sub-epithelial region used in the current trial. This trial has allowed a re-assessment of the uNK cell density test. For the test to select women who need treatment the live birth rate in the screen positive and placebo group needs to be lower than that expected in trials involving similar women. In this feasibility trial, the live birth rate in the placebo group was 40% (CI 12%, 68%), hence lower than the live birth rate in the control group of other recently published RCTs in women with idiopathic RM (Table V) . However, the current trial was not of sufficient size for this finding to reach significance (Table V) . Hence larger trials are needed to confirm or refute the clinical utility of the uNK cell density assessment. Women with very high density of uNK cells (.10%) appeared to have worse outcomes than those with density of 5-10% (Fig. 3) again suggesting that the test has value in stratification of pregnancy outcome. Hence for clinical research on uNK cells to be assessed and for uNK cell density to be used clinically an international standardization is urgently needed and this issue is currently being addressed. Importantly, in this trial the uNK cell density was assessed in a single laboratory to ensure consistency.
The live birth rate was 12/20 (60%) with prednisolone and 8/20 (40%) with placebo (RR 1.5, 95% CI 0.8-2.9, absolute difference 20% CI 210%, +50%). This is a preliminary observation that needs to be interpreted with caution as it does not demonstrate efficacy. Larger trials are needed to demonstrate efficacy and safety.
In conclusion, this pilot RCT has demonstrated that it is feasible and acceptable to the patients to perform an endometrial-based, screen and treat, double-blind, randomized, placebo-controlled trial in women with RM. In the context of idiopathic RM with no other treatments of proven efficacy, we suggest that stratification of pregnancy outcome using an endometrial-based test then randomization to treatment is a potentially important strategy. We have demonstrated that patient willingness for randomization is not a barrier to further trials.
